A comparative study on prognostic differences between men and women with non-small cell lung cancer across different antitumor treatment modalities

Gender is an independent prognostic factor in NSCLC. Male patients generally experience shorter overall survival compared to female patients, particularly in those receiving EGFR-TKI therapy and in certain clinical stages. Gender should be considered in clinical practice when making treatment decisions. Future multicenter prospective studies are needed to further validate these findings and explore the underlying biological mechanisms.